1. World Population Prospects: The 2002 Revision - Highlights. 2003. New York, United Nations. Ref Type: Report. 2. Fuster V, Voute J. MDGs: chronic diseases are not on the agenda. Lancet. 2005; 366(9496):1512-1514. 3. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. [Review] [44 refs]. Circulation. 200; 104(22):2746-2753. 4. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004, 364(9438):937-952. 5. Juan de J. Llibre Rodríguez. Libro Demencias y enfermedad de Alzheimer en la población cubana. Ciudad Habana. Editorial Científico-Técnica, 2008. ISBN. 978-959-05-0544-7. 6. Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M, et al. World Alzheimer Report 2015. The Global Impact of Dementia. An analysis of prevalence, incidence, cost and trends. London: Alzheimer’sDisease International (ADI); 2015. 7. Llibre JJ, Guerra MA, Pérez-Cruz H, Bayarre H, Fernández-Ramirez S, González-Rodriguez M, et al. Síndrome demencial y factores de riesgo en adultos mayores de 60 años residentes en el Municipio Marianao. Rev. Neurol. 1999; 29(10):912-917. 8. Llibre Rodriguez J.J, Ferri C.P, Acosta D, Guerra M, Martin Prince, et al. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. Lancet 2008; 372: 464–74. Published online July 28, 2008 DO1:10.1016/S0140-6736(08)61002-8. 9. Llibre Rodríguez J.J, Valhuerdi A., Sanchez I.I., Reyna C., Guerra M.A, Copeland J.R.M, et al. The prevalence, correlates and impact of dementia in Cuba. A 10/66 Group population-based survey. Neuroepidemiology 2008;31:243–251. 10. Martin Prince, Daisy Acosta, Cleusa P Ferri, Mariella Guerra, Yueqin Huang, Juan J Llibre Rodriguez, et al. Dementia incidence and mortality in middle-income countries, and associations with indicators of cognitive reserve: a 10/66 Dementia Research Group population-based cohort study. The Lancet, Early Online Publication, 23 May 2012. doi:10.1016/S0140-6736(12)60399-7.Bachman DL, Wolf PA, Linn RT. Incidence of dementia and probable Alzheimer’s disease in a general population: the Framingham Study. Neurology. 1993; 43:515–519. 11. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD005593. 12. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomized double-blind trial. Lancet. 2004 Jun 26; 363 (9427):2105–15. 13. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. CurrMed Res Opin. 2005; 21 (8):1317–27. 14. Bullock R, Dengiz A. Cognitive performance in patients with Alzheimer’s disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract. 2005 Jul; 59 (7):817–22. 15. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine Study Group. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003 apr 3; 348:1333–1341. 16. Cano N, Solís J, Jordán J. Evidence for the Efficacy of Latrepirdine (Dimebon) Treatment for Improvement of Cognitive Function: A Meta-Analysis. Journal of Alzheimer’s Disease. 2014; 38: 155–164. 17. Sabbaghand MN, Shill HA. Latrepirdine, a potential novel treatment for Alzheimer’s disease and Huntington’s chorea. Curr Opin Investig Drugs. 2010 Jan; 11(1): 80–91. 18. Brodaty H, Breteler MM, DeKosky ST, Dorenlot P, Fratiglioni L, Hock C, et al. The World of Dementia Beyond 2020J Am Geriatr Soc. 2011 May; 59(5):923-7. 19. Plosker GL, Gauthier S. Cerebrolysin (Renacenz®). A Review of its Use in Dementia. Drugs Aging 2009; 26 (11): 893-915. 20. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008 jul 19; 372:216-23. 21. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmel RA, Ives DG, Saxton JA, et al. Ginkgo biloba for Prevention of Dementia: A Randomized Controlled Trial. JAMA. 2008 Nov 19; 300(19):2253-2262. 22. Los fármacos para el Alzheimer más prometedores en la actualidad. Fármacos para el Alzheimer en Fase III de los ensayos clínicos. [Internet]. Salamanca: TiTi; 2015 [citado 10 Jun 2016]. Disponible en: http://www.2ti.es/2015/07/los-medicamentos-para-el-alzheimer-mas-prometedores-en-la-actualidad/ 23. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014; 370:311-21. 24. Laske C, de la Torre JC. Phase 3 Trials of Solanezumab and Bapineuzumab for Alzheimer’s Disease. N Engl J Med. 2014 april 10; 370 (15):1459-1460. 25. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer ’s disease. N Engl J Med. 2014 Jan 23; 370(4): 322-333. 26. Giuseppe R, Luigi M. Hematologic Consequences of Renal Failure. In: Brenner B.M, editors. Brenner and Rector’s the kidney. Philadelphia: W.B. Saunders; 2000. p. 2079-102. 27. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J BiolChem. 1977 Aug 10; 252(15): 5558-5564. 28. Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridisation. Blood. 1988; 71:524-7 29. Juul SE, Stallings SA, Christensen RD. Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr Res. 1999; 46: 543- 47. 30. Bahadur SPK. Physicochemical and physiological considerations for efficient nose-to-brain targeting. Expert Opin. Drug Deliv. 2012;9(1):19-31. 31. Hanson LR, Frey WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neuroscience. 2008;9 Suppl 3:S5. 32. Brines ML, Ghezzi P, Keenan S, Agnello D, deLanerolle NC, Cerami C, et al. From the cover: erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. ProcNatlAcadSci USA. 2000;19: 10526-31. 33. Sosa I, Cuz J, Santana J, Mengana Y, García-Salman JD, Muñoz A, et al. Paso de la molécula de eritrpopoyetina humana recombinante con bajo contenido de acido sialico al Sistema Nervioso Central por la vía intranasal en los modelos del meriones unguicularus y el primate no humano Macaca fascicularis. Rev. Salud. Anim. 2008;30(1): 39-44. 34. Nuñez Y, Bueno PV, Carrillo DC, et al. Neuroprotective effect of a nasal formulation of erythropoietin with low salicaci content. Rev. Cubana Farm. 2009; 43(1):1-13. 35. Sosa I, García JC, Santana J, et al Intranasal administration of recombinant human erythropoietin exerts neuroprotective effects on post-ischemic brain injury in Mongolian gerbils. Pharmacology Online. 2006;1:100-12. 36. Qi C, Xu M, Gan J, Yang X, Wu N, Song L, et al. Erythropoietin improves neurobehavior by reducing dopaminergic neuron loss in a 6hydroxydopamineinduced rat model. Int J Mol Med. 2014 Aug;34(2):440-50. 37. Lagarto A, Bueno V, Guerra I, Valdes O, Couret M, Lopez R, et al. Absence of hematological side effects in acute and subacute nasal dosing of erythropoietin with a low content of sialic acid. Exp Toxicol Pathol. 2011;63(6):563-7. 38. Youdim MB, Kupershmidt L, Amit T, Weinreb O. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease. Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S132-S136. 39. Erbas O, Cinar BP, Solmaz V, Cavusoglu T, Ates U. The neuroprotective effect of erythropoietin on experimental Parkinson model in rats. Neuropeptides. 2015 Feb;49:1-5. 40. Ansari I, Sheikh A, Ahmed SS, Jabbar Q, Ali S. Management of Anemia and other Hematologic Derangements in Patients with Chronic Kidney Disease. Arab J Nephrol Transplant. 2014 Jan;7(1):13-9. 41. Erbayraktar S, Grasso G, Sfacteria A, Xie Q, Coleman T, Kreilgaard M, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. ProcNatlAcadSci USA. Jul 2003; 100(15): 6741-6746. 42. Sosa I, Mengana Y, Portillo A. Ensayo de seguridad de la aplicación nasal de la molecula de rHu-EPO con bajo contenido de ácido siálico en el modelo de raton B6D2F1. [CD-ROM]. VI Congreso Internacional de Ciencias Veterinarias. Animales de Laboratorio; 2007. 43. Brettschneider J, Riepe M, WidlK, Ehrenreich K, TumaniH. Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases. NeurosciLett. 2006 Sep 1; 404 (3):347-351. 44. Widl K, Brettschneider J, Schattauer D, Süssmuth S, Huber R, Ludolph AC, et al. Erythropoietin in cerebrospinal fluid: age-related reference values and relevance in neurological disease. Neurochem Res. 2007 Jul; 32(7):1163-1168. 45. Assaraf MI, Diaz Z, Liberman A, Miller WH, Arvanitakis Z, Li Y, et al. Brain erythropoietin receptorexpression in Alzheimer disease and mild cognitive impairment. J NeuropatholExp Neurol. 2007May; 66 (5):389-398. 46. Modabberniaa A, Ashrafib M, Modabberniac MJ. Let’s try erythropoietin in Alzheimer’s disease Medical Hypotheses. 2010; 75:270-271. 47. Chong ZZ, Li F, Maiese K. Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. CurrNeurovasc Res. 2005; 2:387–399. 48. Hilger PA. Applied anatomy and physiology of the nose. In: Adams GL, Boies LR, Hilger PA, editors. Boies Fundamentals of Otolaryngology. Philadelphia: W. B. Saunders. 1989. 49. CENPALAB. Evaluación del efecto de la aplicación intranasal de NeuroEPO sobre el número de reticulocitos en el modelo normocitémico de ratón B6D2F1.Informe final 2008. 50. CIDEM. Evaluación de la irritación nasal de una formulación de eritropoyetina humana recombinante con bajo contiendo de ácido siálico. Informe final 2012. 51. CIDEM. Informe de inmunogenicidad a nivel sistémico de una formulación nasal de eritropoyetina humana recombinante con bajo contenido de ácido síalico. Informe final. 2012. 52. CIM. Evaluación de la seguridad de la administración nasal de NeuroEPO en voluntarios sanos. Informe Final. 2013. 53. CIM. Evaluación de la seguridad y efecto del tratamiento con NeuroEPO por vía nasal en pacientes con Ataxia Espinocerebelosa Tipo 2. Informe Final. 2016. 54. Gene S, Koroglu TF, Gene K. Erythropoietin and the nervous system Brain Res. 1000:19-31. 55. Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol. 2001; 60: 386-392 56. Loblaw DA, Holden L, Xenocostas A, et al.Erythropoietin cerebrospinal concentrations and functional outcomes after a single intravenous infusion of epoetin alfa in patients with malignant extradural spinal cord compression. J Clin Oncol. 2004; 22(14S): 1548. 57. Janik P, Kwiecinski H, Sokolowska B, Niebroj-Dobosz I. Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neural Transm. 2010; 117:343–347. 58. FDA, Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. 2005. 59. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J. Basic Clin Pharma 2016; 7:27-31. 60. Ehrenreich H, Degner D, Meller J, et al. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry 2004; 9(1):42–54. 61. Xenocostas A, Cheung WK, Farrell F, et al. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol. 2005; 61(3):189–95. 62. Garcia JC, Sosa I. The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans. ScientificWorldJournal. 2009;9:970-81. 63. CENPALAB. Estudio del efecto de la aplicación intranasal de NeuroEPO sobre algunos parámetros hematológicos y evaluación de efectos adversos en los modelos de la rata SpragueDawley, la especie de primate no humano Macaca Fascicularis, y el modelo de isquemia unilateral permanente en el Gerbo de Mongolia. Informe Final. Febrero. 2012. 64. W.H.O. The causality assessment of suspected adverse reactions 2006. 65. CECMED. Regulación No. 45/2007. 66. CECMED. Regulación 21-08. Requisitos para la autorización y modificación de ensayos clínicos. 2008. 67. Machin, D., Campbell, M., Fayers, P., and Pinol, A. 1997. Sample Size Tables for Clinical Studies, 2nd Edition. Blackwell Science. Malden, MA 68. (Armitage y cols., 2002) 69. Cook J. Predictive probabilities for normal outcomes. Technical notes; September 2011. Available in: http://www.johndcook.com/NormalPredictive.pdf. 70. FDA Draft guidance. Adaptive Design Clinical Trials for Drugs and Biologics. 2010